Advertisement

BM is preferred over PBSCs in transplantation from an HLA-matched related female donor to a male recipient

Hideki Nakasone, Koji Kawamura, Kimikazu Yakushijin, Akihito Shinohara, Masatsugu Tanaka, Kazuteru Ohashi, Shuichi Ota, Naoyuki Uchida, Takahiro Fukuda, Hirohisa Nakamae, Ken-ichi Matsuoka, Junya Kanda, Tatsuo Ichinohe, Yoshiko Atsuta, Yoshihiro Inamoto, Sachiko Seo, Fumihiko Kimura and Masao Ogata

Data supplements

Article Figures & Data

Figures

Tables

  • Table 1.

    Patient characteristics

    FtoM (n = 315)MtoF (n = 260)Matched (n = 557)
    BM, nPBSCs, nPBM, nPBSCs, nPBM, nPBSCs, nP
    Patient age, y.80.59.45
     <5057128.8054109118242
     ≥503892366158139
    Donor age, y.711.00.35
     <505913162116116234
     ≥503689285460146
    Performance status1.00.231.00
     0-19221188159169365
     2-439210716
    CMV serostatus.01.52.36
     No324416384073
     Yes5715869127127287
    Disease.18.25.69
     AML52102398078161
     ALL235926434196
     Lymphoma63110303178
     CML, MPD, MDS142815172646
    rDRI.64.33.41
     Low14247182051
     Intermediate7317578135147304
     High818415622
    HCT-CI.57.55.11
     06413466113128244
     1-2215514343586
     ≥392810231347
    GVHD prophylaxis.07.03.01
     Cyclosporine based7815476122135266
     Tacrolimus based1458124535112
     Other382363
    Conditioning.66.65.59
     Cyclophosphamide + TBI4288376876148
     Busulfan + cyclophosphamide143515343057
     Other MAC204211292266
     Fludarabine RIC165124344397
     Other RIC3435513
    TBI1.00.79.11
     No4092377361159
     Yes551285397115222
    • ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CMV, cytomegalovirus; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; MPD, myeloproliferative disorder; RIC, reduced-intensity conditioning; TBI, total-body irradiation.